TOday’s Movers: AquaBounty Technologies Inc (AQB) Stock Rating Reiterated by H.C. Wainwright; $3.7500 Target Price Indicates 50.60 % Potential

AquaBounty Technologies Inc (AQB) Rating Reaffirmed

The financial firm has just set a target price per share of $3.7500 on AquaBounty Technologies Inc (AQB) shares. This is 50.60 % from the stock close price. In a note revealed to clients on Wednesday morning, H.C. Wainwright kept their “Buy” rating on shares of AQB.

The stock decreased 1.19% or $0.03 during the last trading session, reaching $2.49. About 33,747 shares traded. AquaBounty Technologies, Inc. (AQB) has declined 58.99% since December 2, 2017 and is downtrending. It has underperformed by 74.61% the S&P500.

AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. The company has market cap of $37.60 million. It offers AquAdvantage Salmon, a genetically modified Atlantic salmon for human consumption. It currently has negative earnings. The firm was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004.

More notable recent AquaBounty Technologies, Inc. (NASDAQ:AQB) news were published by: Prnewswire.com which released: “AquaBounty Announces Completion of NASDAQ Listing and Equity Subscription from Intrexon – PR Newswire” on January 19, 2017, also Nasdaq.com with their article: “Stock Market News For Sep 13, 2018 – Nasdaq” published on September 13, 2018, Globenewswire.com published: “AquaBounty wins Gold Leaf Award for Best “Emerging Agriculture Company” from BIOTECanada – GlobeNewswire” on November 16, 2017. More interesting news about AquaBounty Technologies, Inc. (NASDAQ:AQB) were released by: Nasdaq.com and their article: “Three Positive Things About Yesterday’s Gyrations in the Stock Market – Nasdaq” published on October 24, 2018 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 06/20/2018: APEN, MBRX, MNOV – Nasdaq” with publication date: June 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.